These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 19134036

  • 1. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
    Rodriguez-Merchan EC, Hedner U, Heijnen L, Jimenez-Yuste V, Lee CA, Morfini M, Querol F, Roosendaal G, Santagostino E, Solimeno LP.
    Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
    [Abstract] [Full Text] [Related]

  • 2. Orthopaedic surgery in haemophilia patients with inhibitors as the last resort.
    Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V.
    Haemophilia; 2008 Nov; 14 Suppl 6():56-67. PubMed ID: 19134035
    [Abstract] [Full Text] [Related]

  • 3. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U.
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [Abstract] [Full Text] [Related]

  • 4. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
    Rodriguez-Merchan EC.
    Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M, Lambert T.
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [Abstract] [Full Text] [Related]

  • 9. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA.
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 13. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U, Livnat T, Zivelin A, Kenet G.
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [Abstract] [Full Text] [Related]

  • 16. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM.
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA.
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [Abstract] [Full Text] [Related]

  • 19. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
    Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE.
    Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
    [Abstract] [Full Text] [Related]

  • 20. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D, Deryło Ł, Ryś P, Władysiuk M.
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.